On June 10, the REMAP-CAP trial released a preliminary result that suggests that oseltamivir (Tamiflu) is not effective, and may be harmful, in adult patients with influenza in critical care. Oseltamivir is the current first-line treatment for influenza in people who are critically ill, provided to 70-80% of patients with influenza in critical care in Australia. With the peak of...

A vital first step in developing guidelines for early-onset bowel cancer is identifying the clinical topics where guidance is most urgently needed. What areas are likely to have...

ALEC are proud to be partnering with Bowel Cancer Australia to develop clinical practice guidelines for the Diagnosis and Management of Early-Onset Colorectal Cancer. Each year almost 1,900...

Expectations regarding lived experience engagement in health research have shifted considerably in recent years. A 2014 analysis of Australian guidelines, undertaken prior to the publication of the first...

  Applications are now closed for the Australian Living Evidence Collaboration's 2026 Lived Experience Advisory Group ALEC’s vision is a national system delivering up‑to‑date, trustworthy living syntheses of...